Physician profile
Matthew S Markert
NPI 1073951539
$100,336.59
in general payments reported to CMS, 2019-2025
10 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $11K · 2021: $11K · 2022: $8,869 · 2023: $23K · 2024: $31K · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,897.25 |
| Food and Beverage | $1,181.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $97,858.86 | 2019-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Livanova USA, INC. | $1,403.85 | 2021-2022 | |
| Abbvie INC. | $356.62 | 2022-2025 | |
| Boston Scientific Corporation | $320.99 | 2020-2024 | |
| Neurocrine Biosciences, INC. | $125.69 | 2025 | |
| Ucb, INC. | $124.99 | 2019 | |
| Neurelis, INC. | $98.62 | 2023 | Valtoco |
| Sk Life Science, INC. | $22.21 | 2025 | |
| Zogenix INC. | $12.60 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Markert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.